Samarium-153 EDTMP Therapy of Disseminated Skeletal Metastasis

Overview

Journal Eur J Nucl Med

Specialty Nuclear Medicine

Date 1989 Jan 1

PMID 2483138

Citations 15

Authors

J H Turner

A A Martindale

P Sorby

E L Hetherington

R F Fleay

R F HOFFMAN

P G Claringbold

Affiliations

Soon will be listed here.

Abstract

153Sm-EDTMP (ethylenediaminetetramethylene phosphonate), prepared from a kit, was administered to 28 patients in a clinical trial of therapy for painful skeletal metastases unresponsive to all conventional treatment. The 103 keV gamma emission of 153Sm was utilized for prospective individual estimation of beta radiation absorbed dose to red marrow to minimize myelotoxicity and provide optimum internal radiotherapy to skeletal metastases in each patient. Pain relief occurred within 14 days of administration of 153Sm-EDTMP in 15 of 19 patients (79%) who could be evaluated at 6 weeks, when clinical response was maximal. Duration of response ranged from 4 to 35 weeks. Recurrence of pain responded to retreatment with 153Sm-EDTMP in five of eight cases. No dose-response relationship was apparent for pain relief but reversible myelotoxicity was frequently observed at radiation absorbed doses to bone marrow greater than or equal to 270 cGy. Dosimetry calculation was based on pharmacokinetic studies of a tracer administration of 153Sm-EDTMP in each patient. Assumptions inherent in this prospective method of predicting dose to bone marrow were validated experimentally. Biodistribution studies in rats demonstrated rapid skeletal uptake and long term retention of 153Sm-EDTMP in bone over 5 days. Urinary clearance accounted for 40% of injected dose, and less than 1.0% of administered activity was retained in non osseous tissue. Microdensitometry of autoradiographs of sheep vertebra and femur confirmed surface uptake of 153Sm-EDTMP in cortical bone and demonstrated relatively high trabecular bone activity which is the major component of radiation absorbed dose to bone marrow. Haematological studies in rabbits showed 153Sm-EDTMP-induced myelotoxicity to be transient and no histopathological abnormalities were demonstrable with doses ten times greater than those administered to patients.

Citing Articles

Bisphosphonates as Radiopharmaceuticals: Spotlight on the Development and Clinical Use of DOTAZOL in Diagnostics and Palliative Radionuclide Therapy.

Souche C, Fouillet J, Rubira L, Donze C, Deshayes E, Fersing C Int J Mol Sci. 2024; 25(1).

PMID: 38203632 PMC: 10779041. DOI: 10.3390/ijms25010462.

Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain.

Manafi-Farid R, Masoumi F, Divband G, Saidi B, Ataeinia B, Hertel F J Clin Med. 2020; 9(8).

PMID: 32806765 PMC: 7464823. DOI: 10.3390/jcm9082622.

Comparison of Tc-99m MDP and Sm-153 EDTMP bone scan.

Ramachandran K, Kathiresan , Begum B, Rangarajan Indian J Nucl Med. 2013; 26(3):163-4.

PMID: 23326073 PMC: 3543587. DOI: 10.4103/0972-3919.104005.

Prospective dosimetry with 99mTc-MDP in metabolic radiotherapy of bone metastases with 153Sm-EDTMP.

Bianchi L, Baroli A, Marzoli L, Verusio C, Chiesa C, Pozzi L Eur J Nucl Med Mol Imaging. 2008; 36(1):122-9.

PMID: 18751975 DOI: 10.1007/s00259-008-0926-7.

The management of painful bone metastases with an emphasis on radionuclide therapy.

Hillegonds D, Franklin S, Shelton D, Vijayakumar S, Vijayakumar V J Natl Med Assoc. 2007; 99(7):785-94.

PMID: 17668645 PMC: 2574338.

References

Blake G, Zivanovic M, McEwan A, Batty V, Ackery D . 89Sr radionuclide therapy: dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma. Eur J Nucl Med. 1987; 13(1):41-6. DOI: 10.1007/BF00252645. View

HENDRICKSON F, Sheinkop M . Management of osseous metastases. Semin Oncol. 1975; 2(4):399-404. View

Firusian N, MELLIN P, SCHMIDT C . Results of 89strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. J Urol. 1976; 116(6):764-8. DOI: 10.1016/s0022-5347(17)59002-3. View

Blake G, Gray J, Zivanovic M, McEwan A, Fleming J, Ackery D . Strontium-89 radionuclide therapy: a dosimetric study using impulse response function analysis. Br J Radiol. 1987; 60(715):685-92. DOI: 10.1259/0007-1285-60-715-685. View

Mathieu L, Chevalier P, Galy G, Berger M . Preparation of rhenium-186 labelled EHDP and its possible use in the treatment of osseous neoplasms. Int J Appl Radiat Isot. 1979; 30(12):725-7. DOI: 10.1016/0020-708x(79)90150-9. View

Kutzner J, Dahnert W, Schreyer T, Grimm W, Brod K, Becker M . [Treatment of pains from bone metastases with 90Y (author's transl)]. Nuklearmedizin. 1981; 20(5):229-35. View

Coursey B, Hoppes D, Schima F, Unterweger M . The standardization of samarium-153. Int J Rad Appl Instrum A. 1987; 38(1):31-4. DOI: 10.1016/0883-2889(87)90232-2. View

Eisenhut M . Iodine-131-labeled diphosphonates for the palliative treatment of bone metastases: I. Organ distribution and kinetics of I-131 BDP3 in rats. J Nucl Med. 1984; 25(12):1356-61. View

Eisenhut M, Berberich R, Kimmig B, Oberhausen E . Iodine-131-labeled diphosphonates for palliative treatment of bone metastases: II. Preliminary clinical results with iodine-131 BDP3. J Nucl Med. 1986; 27(8):1255-61. View

10.

Rossleigh M, Lovegrove F, Reynolds P, Byrne M . Serial bone scans in the assessment of response to therapy in advanced breast carcinoma. Clin Nucl Med. 1982; 7(9):397-402. DOI: 10.1097/00003072-198209000-00001. View

11.

Robinson R, Spicer J, PRESTON D, WEGST A, Martin N . Treatment of metastatic bone pain with strontium-89. Int J Rad Appl Instrum B. 1987; 14(3):219-22. DOI: 10.1016/0883-2897(87)90045-6. View

12.

Spencer R . Short lived radionuclides in therapy. Int J Rad Appl Instrum B. 1987; 14(6):537-8. DOI: 10.1016/0883-2897(87)90022-5. View

13.

Turner J, Martindale A, de Witt G, Webb J, Sorby P, Boyd R . Samarium-153 chelate localization in malignant melanoma. Eur J Nucl Med. 1987; 13(8):432-8. DOI: 10.1007/BF00292499. View

14.

Goeckeler W, Edwards B, Volkert W, Holmes R, Simon J, Wilson D . Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med. 1987; 28(4):495-504. View

15.

BUCHALI K, CORRENS H, Schuerer M, Schnorr D, Lips H, Sydow K . Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med. 1988; 14(7-8):349-51. DOI: 10.1007/BF00254382. View

16.

CORRENS H, MEBEL M, BUCHALI K, Schnorr D, Seidel C, MITTERLECHNER E . 89Strontium therapy of bone metastases of carcinoma of the prostatic gland. Eur J Nucl Med. 1979; 4(1):33-5. DOI: 10.1007/BF00257567. View

17.

WALLENSTEIN S . Measurement of pain and analgesia in cancer patients. Cancer. 1984; 53(10 Suppl):2260-6. DOI: 10.1002/cncr.1984.53.s10.2260. View

18.

Maxon H, Deutsch E, Thomas S, Libson K, Lukes S, Williams C . Re-186(Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology. 1988; 166(2):501-7. DOI: 10.1148/radiology.166.2.3122267. View

19.

Logan K, Volkert W, Holmes R . Radiation dose calculations in persons receiving injection of samarium-153 EDTMP. J Nucl Med. 1987; 28(4):505-9. View

20.

FRIEDELL H, STORAASLI J . The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to bone. Am J Roentgenol Radium Ther. 1950; 64(4):559-75. View